Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2024

According to the American Cancer Society, in 2024, over 600,000 individuals in the United States are expected to die from cancer. As a result, the emphasis on developing high-efficacy therapies for treatment is at its peak. With collaborations between biotech companies, research and academic institutions, oncolytic virus therapies are witnessing accelerated development and commercialization.

Key Takeaways

• Continuous progress in clinical trials along with regulatory approvals from regulatory authorities like the United States FDA are boosting the market growth for oncolytic virus cancer therapies.

• Technical advancements in delivery systems, and virus engineering leading to enhanced efficacy of oncolytic virus therapies is among major market trends.

• Some of the key drugs currently in the pipeline include CF33-hNIS, R130, LOAd703 and OH2, among others.

Report Coverage

The Oncolytic Virus Cancer Therapy Pipeline Report by Expert Market Research gives comprehensive insights on the drugs currently undergoing clinical trials. It covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to oncolytic virus cancer therapy are covered.

Oncolytic Virus Cancer Therapy Pipeline Outlook

Oncolytic virus cancer therapy involves the administration of a virus to attack the tumor cells in a cancer patient's body. These cancer cells infecting virus cells replicate at a fast pace and destroy tumor cells by opening their exterior and exposing the cell content to the immune system.

Only one oncolytic virus, T-VEC (talimogene laherparepvec) has been approved by the United States FDA for metastatic melanoma. Approved in 2015, T-VEC (Imlygic®) is a modified version of herpes simplex virus (HSV). It has been modified to infect cancer cells to produce GM-CSF (an immune-stimulating protein).

These viruses are designed in a way to target cancer cells by identifying its abnormalities such as mutations or differences on the cell surface of proteins. The study of oncolytic therapies is based on several virus types such as adenoviruses, herpes simplex viruses, poxviruses, and others. Each type of virus has a unique characteristic that influences its safety and efficacy against a distinct type of cancer cell. Several oncolytic therapy drugs are currently under clinical trials.

The Oncolytic Virus Cancer Therapy Pipeline Report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.

Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment

This section of the report covers the analysis of oncolytic virus cancer therapies based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analysis based on phase.

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analysis based on the route of administration.

• Oral

• Parenteral

• Others

Oncolytic Virus Cancer Therapy – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, phase I trials cover a major share of the total clinical trials conducted, with approximately 40 plus drugs in the pipeline.

Oncolytic Virus Cancer Therapy – Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under the oncolytic virus cancer therapy pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.

Oncolytic Virus Cancer Therapy Clinical Trials Assessment – Competitive Dynamics

The EMR report for the oncolytic virus cancer therapy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:

• Oncostar LLC

• Lokon Pharma AB

• Binhui Biopharmaceutical Co., Ltd.

• Hangzhou Converd Co., Ltd.

• Syneos Health, Inc.

• Astellas Pharma Global Development, Inc.

• Johnson & Johnson Enterprise Innovation Inc.

Oncolytic Virus Cancer Therapy – Pipeline Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of oncolytic virus cancer therapy clinical trial drugs.

CF33-hNIS

It is an oncolytic virus monotherapy candidate that is being investigated for gastrointestinal cancer treatment by a team of researchers at the Karmanos Cancer Center in Detroit, United States. CF33-hNIS has started demonstrating evidential efficacy against the condition.

R130

This oncolytic virus injection is being evaluated for advanced solid tumor treatment. Sponsored by Shanghai Yunying Medical Technology, this recombinant oncolytic herpes simplex virus type 1 (R130) is under investigation against breast cancer and pancreatic cancer.

LOAd703

An oncolytic adenovirus, LOAd703 is under evaluation to treat pancreatic cancer in patients. As a part of the study, it will be administered via intramural injections and will be added to standard-of-care treatment with gemcitabine and nab-paclitaxel.

OH2

Developed by making genetic alterations in the herpes simplex virus type 2 strain HG52, OH2 oncolytic cancer is under trials for locally advanced or metastatic bladder cancer. Currently evaluated in the BH-OH2-017 multicenter clinical trial, it will be delivered once every two weeks. However, the injection dosage will be reduced to once a month during the maintenance treatment period.

Key Questions Answered in the Oncolytic Virus Cancer Therapy – Pipeline Assessment Report

• What is the current landscape of oncolytic virus cancer therapy drugs?
• How many companies are developing oncolytic virus cancer therapies?
• How many phase I and phase II drugs are currently present in oncolytic virus cancer therapies?
• Which companies/institutions are leading the oncolytic virus cancer therapy development?
• What is the efficacy and safety profiles of oncolytic virus cancer therapy?
• What are the opportunities and challenges present in the oncolytic virus cancer therapy landscape?
• Which company is conducting major trials for oncolytic virus cancer therapy?
• What are the geographies covered for clinical trials in oncolytic virus cancer therapy?
• What are emerging trends in oncolytic virus cancer therapy clinical trials?

Related Reports

Cancer Screening Market

Cancer Therapeutics Market